1. Executive Summary (Plain English)

Purpose: This independent review evaluates Ms. Angela Vance’s current medication regimen for drug-related factors contributing to worsening confusion, daytime sedation, gait instability/fall risk, and nocturnal agitation. It establishes actionable steps to discuss with her treating physician while identifying immediate safety modifications.

High-Level Clinical Findings:

• Direct Pharmacologic Antagonism: Ms. Vance is taking a prescribed acetylcholinesterase inhibitor (Donepezil) to preserve memory, while simultaneously taking two over-the-counter anticholinergic drugs (Diphenhydramine and Tylenol PM). Diphenhydramine directly blocks the brain receptors Donepezil is trying to stimulate, rendering her dementia treatment largely ineffective while causing acute confusion and dry mouth.
• High Sedation & Fall Risk (AGS Beers Criteria®): Daily use of Lorazepam (a benzodiazepine) combined with OTC sedating antihistamines creates a heavy cumulative central nervous system (CNS) burden, directly linked to her recent daytime lethargy and two reported fall incidents.
• Unintentional OTC Duplication: Tylenol PM contains diphenhydramine. Combining standalone Benadryl with Tylenol PM results in cumulative supratherapeutic diphenhydramine exposure.

Recommended Next Steps Summary:

• Immediate (Pharmacist Guidance): Discontinue OTC Diphenhydramine and Tylenol PM; transition pain management to plain Acetaminophen under recommended maximum daily limits. Implement nighttime safety precautions.
• Prescriber Orders Needed (Requires Physician Review): Initiate a gradual, medically supervised taper of Lorazepam; re-evaluate Donepezil's baseline efficacy after OTC washout; assess indication for long-term Omeprazole therapy.

2. Medication List & Key Findings Table

Non-Medication / Behavioral Exposures Identified:

• Administration Timing: Hydrochlorothiazide taken at 7:00 PM (causing nighttime awakenings to use the bathroom, increasing fall risk).
• OTC Access: Patient has unrestricted access to nightstand OTC sleep remedies.

3. Cognitive Impact Review (Core Clinical Portion)

3.1 Anticholinergic Burden & Pharmacologic Antagonism

• Evaluation Tool: Anticholinergic Cognitive Burden (ACB) Scale.
• Score: Cumulative ACB Score = 3+ (High Risk for Cognitive Impairment & Mortality).
• Mechanism of Conflict: Donepezil increases acetylcholine levels in the brain to support memory. Diphenhydramine crosses the blood-brain barrier and blocks central acetylcholine receptors. These two medications are actively canceling each other out. This "pharmacologic tug-of-war" frequently presents as acute delirium or accelerated dementia progression.

3.2 Sedation & Psychomotor Impairment (Fall Risk)

• Benzodiazepine Risk: Lorazepam significantly impairs balance, reaction time, and short-term memory in patients over 65. The risk of hip fracture and fall-related head trauma increases exponentially when benzodiazepines are combined with sedating antihistamines.
• Caregiver Observations: Caregiver notes confirm a direct timeline: daytime drowsiness and unsteady gait escalated within 2 weeks of adding regular OTC nighttime sleep aids.

3.3 Long-Term PPI Risk Factors

• Prolonged Omeprazole use (>1 year) impairs Vitamin B12 absorption. B12 deficiency is an established, reversible cause of cognitive slowing and peripheral neuropathy in older adults.

4. Prioritized Optimization Opportunities

Priority Tier 1: High Impact & Safety-Critical

1. Immediate OTC Discontinuation (Diphenhydramine & Tylenol PM):
   • Pharmacist Action: Counsel family to stop OTC sleep aid administration immediately. Replace with plain Acetaminophen (Tylenol Regular/Extra Strength) for joint pain, not to exceed 2,000 mg–3,000 mg total daily dose.
   • Prescriber Discussion: Inform PCP of OTC washout to establish a true cognitive baseline.
2. Lorazepam (Ativan) Deprescribing Plan:
   • Requires Prescriber Order: Do not stop Lorazepam abruptly due to risk of withdrawal, rebound anxiety, and seizures.
   • Proposed Action: Discuss a gradual dose reduction schedule (e.g., reduce daily dose by 25% every 1–2 weeks) alongside non-pharmacologic anxiety protocols.

Priority Tier 2: Moderate Impact & Dosing Adjustments

1. Diuretic Administration Timing:
   • Pharmacist Advice: Move Hydrochlorothiazide from evening to morning (with breakfast) to eliminate nocturnal polyuria and reduce nighttime trip-and-fall hazards.
2. Omeprazole Deprescribing / Re-evaluation:
   • Prescriber Discussion: Evaluate if ongoing daily PPI therapy is clinically indicated or if step-down to H2RA (e.g., Famotidine) or PRN antacids is appropriate. Request serum Vitamin B12 and magnesium levels.

5. Monitoring & Safety Plan

Daily Caregiver Tracking Log (7–14 Days Post-OTC Discontinuation):

• Morning Alertness: Score 1–5 (1 = Lethargic, 5 = Fully Awake).
• Gait Stability: Note any unsteadiness, near-misses, or loss of balance.
• Nocturnal Awakenings: Record frequency and causes (e.g., bathroom visit vs. agitation).
• Pain Levels: Record joint pain control using plain Acetaminophen.

6. Clinician Discussion & Legal / Administrative Scope Notes

Delineation of Scope:

• Pharmacist Direct Recommendations (Within Scope): Discontinuation of unsafe OTC self-care products, patient/caregiver education on OTC drug interactions, recommendation of non-pharmacologic sleep hygiene strategies, advice on OTC pain management limits, and medication timing optimization (moving diuretic to AM).
• Prescriber-Led Actions (Requires Medical Doctor Orders): Alteration, dose reduction, tapering, or cessation of prescription medications (Lorazepam, Donepezil, Omeprazole, Amlodipine, HCTZ); ordering laboratory work (B12, BMP, Magnesium); formal diagnostic assessment of cognitive changes.